Last $157.23 USD
Change Today -2.23 / -1.40%
Volume 249.9K
IDXX On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

idexx laboratories inc (IDXX) Key Developments

IDEXX Launches New Reagents for Detection of Swine Enteric Coronaviruses

IDEXX Laboratories, Inc. has launched a set of RealPCR reagents to detect viral agents that cause contagious and acute diarrheal diseases in swine. Laboratories can now detect and differentiate between RNA of these swine enteric coronaviruses using three disease-specific assays and a multiplex assay, all of which run on the IDEXX RealPCR Modular System. Used to facilitate detection of virus and differentiate between viral species, the swine enteric coronavirus polymerase chain reaction (PCR) assays include the RealPCR PEDV RNA Reagents for porcine epidemic diarrhea virus, the RealPCR PDCoV RNA Reagents for porcine deltacoronavirus, the RealPCR TGEV RNA Reagents for transmissible gastroenteritis virus and the RealPCR PEDV/PDCoV Multiplex RNA Reagents. The assays can be run side by side on a single plate, maintaining fast run protocols and increasing laboratory work-flow efficiency. RealPCR swine enteric coronavirus assays are part of the RealPCR Modular System, which provides standardization at every level of real-time PCR testing. The modular system allows laboratories to order components separately, eliminating the concept of traditional real-time PCR kits and maximizing efficiency. Each assay has built-in quality controls and is supported by the IDEXX RealPCR Quality Control System, ensuring complete control at every step.

IDEXX Laboratories Launches Somatic Cell Counts Test

IDEXX Laboratories, Inc. launched IDEXX Somaticell SCC Test, an on-farm test that reportedly eliminates the guesswork about somatic cell counts, or SCC, in raw cow milk. The new test will be available in the US, Canada and Latin America. By using the Somaticell SCC Test, producers can get clear-cut results on-farm in less than 2 minutes, allowing them to make real-time decisions about how to manage SCC levels. Knowing whether a somatic cell count is low or high gives producers a better understanding of each cow's health and more options for ensuring milk quality and overall herd health. High somatic cell counts have been linked to declines in production and poor milk quality and can also indicate that roughly one in three cows in a herd may be infected with subclinical mastitis.

IDEXX Laboratories, Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-03-2015 10:25 AM

IDEXX Laboratories, Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-03-2015 10:25 AM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, FL 32837, United States. Speakers: Brian P. McKeon, Chief Financial Officer, Principal Accounting Officer, Executive Vice President and Treasurer.

IDEXX Laboratories, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year of 2015

IDEXX Laboratories, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, revenue was $351,959,000 against $354,073,000 a year ago. Net income attributable to stockholders was $25,961,000 against $43,258,000 a year ago. Earnings per share diluted were $0.54 against $0.82 a year ago. Adjusted diluted earnings per share were $0.54 against $0.82 a year ago. For the year, revenue was $1,485,807,000 against $1,377,058,000 a year ago. Net income attributable to stockholders was $181,906,000 against $187,800,000 a year ago. Earnings per share diluted were $3.58 against $3.48 a year ago. Adjusted diluted earnings per share were $3.58 against $3.48 a year ago. Net cash provided by operating activities was $235,846 against $245,996 a year ago. Purchases of property and equipment were $60,523 against $77,612 a year ago. Acquisitions of intangible assets were $175,000 against $1,024,000 a year ago. For the full year of 2015, the company is updating its financial guidance, in part to reflect the significant strengthening of the USD relative to foreign currencies. At current foreign exchange rates, the company estimates that the effect of the stronger USD will adversely impact 2015 reported revenue growth by approximately 5% and EPS by an estimated $0.22 per share compared to rates in effect in 2014. The continued strengthening of the USD has the effect of lowering projected revenue by approximately $55 million and EPS by $0.13 per share. These effects are mitigated by the Company's raised expectation for normalized organic revenue growth and assumptions for a 30% effective tax rate, resulting in a net $0.05 per share reduction in its 2015 EPS guidance range compared to its prior guidance provided in October of 2014. Revenue expected to report $1,640 million to $1,660 million, normalized organic revenue growth 13.5% to 14.5%, EPS of $4.33 to $4.43, free cash flow of 90% to 100% of net income. Capital expenditures of $85 million. The company expects an effective tax rate of 30%. The comparison of 2015 guidance excluding the federal R&D tax credit, to 2014 results including this tax credit, reduces projected Adjusted EPS growth by 2%.

IDEXX Laboratories Launches Its New Kidney Test Called SDMA

IDEXX Laboratories announced that it launched its new kidney test, called SDMA to transform the way veterinarians diagnose and treat kidney disease in cats and dogs. The company added that the new IDEXX SDMA test has been shown to detect kidney disease when only 40% function has been lost, on average, and in some cases even earlier, allowing veterinarians to provide more effective intervention, including prescription of therapeutic diets, renal protective drugs and avoidance of renal toxic drugs. This new test incorporates proprietary technology that allows SDMA to be measured on routine high throughput clinical chemistry analyzers used in its reference labs in a highly cost effective fashion and at the same rapid turnaround time as the rest of a chemistry panel, according to the company. In conjunction, the company intends to include the SDMA kidney test in all routine reference lab chemistry profiles at no additional cost to the customer. More than half request for a chemistry panel and almost all customers who use IDEXX as their primary reference lab routinely request lab requisitions that include chemistry testing.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDXX:US $157.23 USD -2.23

IDXX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DENTSPLY International Inc $53.08 USD -0.34
MEDNAX Inc $70.57 USD -0.66
ResMed Inc $64.49 USD -0.27
Siemens Ltd 1,437 INR +8.35
Cooper Cos Inc/The $164.77 USD -0.96
View Industry Companies
 

Industry Analysis

IDXX

Industry Average

Valuation IDXX Industry Range
Price/Earnings 44.5x
Price/Sales 5.1x
Price/Book 64.3x
Price/Cash Flow 41.3x
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDEXX LABORATORIES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.